Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials

Predict Severe Traumatic Brain Injury

NCT06966713
Recruiting
Conditions Traumatic Brain Injury
Phase Not Applicable
Enrollment 120
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Severe traumatic brain injury (TBI) is associated with a 20-30% mortality rate and significant disability among most survivors. The Centers for Disease Control and Prevention (CDC) estimate that 2% of the U.S. population lives with disabilities directly attributable to TBI, with annual costs exceeding $76.5 billion. Current treatments are largely ineffective because they are instituted after irreversible damage has already occurred. By the time intracranial pressure (ICP) increases or brain tissue oxygen tension (PbtO2) decreases to harmful levels, it is often too late to reverse or repair the damage. A computerized method has been developed that can predict these injurious events ahead of time, allowing clinicians to intervene before further damage occurs. The goal of this proposal is to test these predictions in real time. The first phase of the project (Year 1) involves setting up the informatics infrastructure, with no patient interaction. In the second phase (Year 2), subjects, through surrogate decision-makers, will be enrolled in an observational study where data on intracranial pressure and brain tissue oxygen tension will be collected, and the prediction algorithm will be tested for accuracy. Clinical management will follow standard care protocols, and no additional interventions will be performed. Approximately 120 individuals will participate in this study at the University of Chicago and Ben Taub General Hospital in Houston. Data collected will include both the electronic medical record and data from bedside intensive care unit monitors. The electronic medical record includes demographic information, injury characteristics, laboratory values, and imaging data, while the intensive care unit monitor provides real-time vital signs such as intracranial pressure, brain tissue oxygen tension, and mean arterial pressure. These data will be securely stored in a research computer database. Efforts will be made to contact subjects or their caretakers at 6 months to follow up on recovery. This research aims to improve patient outcomes by providing predictions of further brain injury, with the potential for future interventions to prevent permanent brain damage.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Modified Rankin Scale (mRS) (3, 6, and 12 months post-discharge)
  • Rivermead Post-Concussion Symptoms Questionnaire (RPQ) (3, 6, and 12 months post-discharge)
  • Glasgow Outcome Scale-Extended (GOSE) (3, 6, and 12 months post-discharge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-02-20
Completion: 2026-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Chicago
Collaborators: United States Department of Defense, Baylor College of Medicine
Principal Investigators:
  • Christos Lazaridis, MD (PRINCIPAL_INVESTIGATOR) - clazaridis@bsd.uchicago.edu
Contact Information
Study Contact:
Farima Fakhri, MD
7737021220
Farima.Fakhri@bsd.uchicago.edu
Farima Fakhri, MD
773-702-1220
farima.fakhri@bsd.uchicago.edu
University of Chicago
Christos Lazaridis, MD
University of Chicago
Interventions
N/A
Study Locations (2 sites)
University of Chicago, Chicago, Illinois 60637 United States
Baylor college of medicine, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Patients age \>18 years old * Severe TBI, determined by initial Glasgow Coma Scale (GCS) score after resuscitation and without the influence of paralytics or sedation, (GCS score ≤8, motor score ≤5, not following commands) * The clinical need for ICP and/or PbtO2 monitoring according to the BTF guidelines * Be able to enroll during the course of their stay in the ICU Exclusion Criteria: * Neurological exam suggesting imminent brain death (bilateral, fixed and dilated pupils) or questionable accuracy of the neurologic exam (high blood alcohol level and/or seizure activity \< 30 minutes of exam) * Evidence of pregnancy (urine or blood test) * Placement of intracranial monitoring is contraindicated (e.g., uncorrected coagulopathy, depressed skull fracture) * Inability to obtain informed consent from legal authorized representative (LAR) prior to research procedures * Participation in another interventional clinical trial (coenrollment with the BOOST3 (CIRB19-0228) trial is allowed\*) * Prisoner
Conditions Preeclampsia (PE)
Phase NA
Enrollment 14500
Locations 22 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine whether first-trimester screening for preeclampsia based on the FMF algorithm (a combination of maternal clinical, sonographic and biochemical parameters), improves maternal or perinatal health.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Procedure: First-trimester preeclampsia screening (FMF triple test) — An algorithm assessing the risk of developing preeclampsia combining maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentrations. For women in the screening group, a Doppler study of the uterine arteries and a blood test to quantify PlGF concentrations will be performed within 2 days of randomization, allowing the risk to be calculated according to the screening test. For women with a positive screening test (i.e. predicted risk\> 1/100), a treatment with aspirin will be prescribed at 160 mg/day, started as soon as possible and before 15 WG, and taken up to 36 WG, in the absence of contraindications. For women with negative screening, usual pregnancy monitoring without aspirin will be offered.

Primary Outcomes

  • Severe perinatal morbidity (From birth up to 7 days of life)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-06
Completion: 2027-02
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 14500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Collaborators: INSERM, Epopé team, URC-CIC Paris Descartes Necker Cochin
Principal Investigators:
  • Catherine DENEUX, MD, PhD (STUDY_DIRECTOR) - Institut National de la Santé Et de la Recherche Médicale, France
Contact Information
Study Contact:
Vassilis TSATSARIS, MD, PhD
01 58 41 38 71
vassilis.tsatsaris@aphp.fr
Valérie PLENCE, MSc
01 58 41 11 78
valerie.plence-fauroux@aphp.fr
Guillaume LEGENDRE
guillaume.legendre@chu-angers.fr
CHU Angers
Interventions
  • Procedure: First-trimester preeclampsia screening (FMF triple test) — An algorithm assessing the risk of developing preeclampsia combining maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentrations. For women in the screening group, a Doppler study of the uterine arteries and a blood test to quantify PlGF concentrations will be performed within 2 days of randomization, allowing the risk to be calculated according to the screening test. For women with a positive screening test (i.e. predicted risk\> 1/100), a treatment with aspirin will be prescribed at 160 mg/day, started as soon as possible and before 15 WG, and taken up to 36 WG, in the absence of contraindications. For women with negative screening, usual pregnancy monitoring without aspirin will be offered.
Study Locations (22 sites)
CHU Angers, Angers, France
CHU de Bordeaux, Bordeaux, France
Hôpital Femme Mère Enfant, Bron, France
Hôpital Antoine Béclère, Clamart, France
CHU Estaing, Clermont-Ferrand, France
Hôpital Intercommunal Créteil, Créteil, France
CHU Dijon Bourgogne, Dijon, France
CHU Lille, Lille, France
Hôpital de la conception et de la Timone, Marseille, France
Hôpital Nord, Marseille, France
Eligibility Criteria
Inclusion Criteria : * Pregnancy between 11 and 14 WG * Age ≥18 years * Affiliated to or beneficiary of a health insurance system (including AME) * Signed informed consent Exclusion Criteria : * Gestational age \<11 WG or \>14 WG * Known ectopic pregnancy * Known non-ongoing pregnancy * Known multiple pregnancy * History of PE in a previous pregnancy * Pregnancies complicated by major fetal abnormality identified at the first-trimester ultrasound if performed before randomization * Absence of health insurance * Contra-indication to aspirin (bleeding disorders such as von Willebrand's disease, active peptic ulceration, hypersensitivity to aspirin, active peptic ulceration, NSAID-exacerbated respiratory disease, severe liver or heart dysfunction) * Women taking low-dose aspirin regularly and started before pregnancy (except ART indication) * Age \<18 years * Poor understanding of the French language
Conditions Intrahepatic Cholangiocarcinoma (Icc), G...
Phase PHASE2
Enrollment 33
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

For advanced unresectable intrahepatic cholangiocarcinoma and gallbladder cancer, the current standard first-line treatment is a combination of chemotherapy and immunotherapy. However, the efficacy rates remain low. Hepatic artery infusion chemotherapy can reduce systemic drug dosages while increasing local drug concentrations, which is expected to enhance overall efficacy and minimize drug toxicity and side effects. This study utilized a hepatic artery infusion chemotherapy regimen that combines gemcitabine with oxaliplatin, along with the small molecule tyrosine kinase inhibitor lenvatinib and the immune checkpoint inhibitor toripalimab. The aim was to improve treatment efficacy and create opportunities for conversion surgery. The primary endpoint was the objective response rate, while the secondary endpoints included the surgical resection rate, complete pathological response rate (pCR), overall survival (OS), and the incidence of adverse reactions.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab. — Toripalimab: 240mg ivd d1, q3w; Lenvatinib: 8-12mg po qd (body weight\<60kg, 8mg po qd; body weight ≥ 60kg, 12mg po qd) Chemotherapy by hepatic arterial infusion (GOLD HAIC): d1 oxaliplatin: 100-125mg+gemcitabine: 800-1000mg; q3w.

Primary Outcomes

  • Objective Response Rate (ORR) (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-09-01
Completion: 2026-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 33 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital
Contact Information
Study Contact:
Tianjin Medical University Cancer Institute and Hospital Department of Hepatobiliary Cancer
86-2223340123
zhang.wei@tmu.edu.cn
wei zhang, surgical chief physician, M.D., Ph.D.
8618622025401
zhang.wei@tmu.edu.cn
Tianjin Medical University Cancer Institute and Hospital Department of Hepatobiliary Cancer
8618622025401
zhang.wei@tmu.edu.cn
Tianjin Medical University Cancer Institute and Hospital
Interventions
  • Drug: chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab. — Toripalimab: 240mg ivd d1, q3w; Lenvatinib: 8-12mg po qd (body weight\<60kg, 8mg po qd; body weight ≥ 60kg, 12mg po qd) Chemotherapy by hepatic arterial infusion (GOLD HAIC): d1 oxaliplatin: 100-125mg+gemcitabine: 800-1000mg; q3w.
Study Locations (1 sites)
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tia 300060 China
Eligibility Criteria
Inclusion Criteria 1. Age 18 or above 2. Histopathological or cytological diagnosis of intrahepatic cholangiocarcinoma or gallbladder cancer 3. A tumor that cannot be removed by three independent surgeons. 4. Expected lifespan ≥ 12 weeks 5. ECOG PS score 0-1 points 6. The patient voluntarily participates and signs an informed consent form; 7. Expected compliance is good, able to follow up on efficacy and adverse reactions according to the protocol requirements. Exclusion criteria: 1. Use any systemic research anti-cancer drugs 2. Active autoimmune diseases or a history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (which may include hormone replacement therapy) 3. Asthma requires the use of bronchodilators for medical intervention 4. Congenital or acquired immune dysfunction, such as human immunodeficiency virus (HIV) infection 5. Clinical symptoms or uncontrolled heart disease 6. Severe infection within 4 weeks before the first use of medication 7. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation 8. Vaccination with attenuated live vaccine within 4 weeks before treatment 9. Other systemic malignant tumors in the past 5 years
Conditions Glaucoma, Ocular Hypertension
Phase PHASE4
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Drug: Netarsudil Ophthalmic Solution (Rhopressa) — Netarsudil ophthalmic solution is an FDA-approved Rho kinase inhibitor indicated for the treatment of ocular hypertension and open-angle glaucoma. In this study, it will be administered once daily in the evening for approximately 14 days.
  • Other: Artificial Tears (AT) — Artificial tears will be used as a placebo control and administered once daily in the evening for approximately 14 days. These drops are not expected to lower intraocular pressure or alter trabecular meshwork structure.

Primary Outcomes

  • Change in Trabecular Meshwork Lamellae Spacing (Baseline to 14-21 days after initiation of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-06-05
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Indiana University
Collaborators: Alcon Research
Contact Information
Study Contact:
Brett J King, OD
(812) 855-1344
kingbrj@iu.edu
Interventions
  • Drug: Netarsudil Ophthalmic Solution (Rhopressa) — Netarsudil ophthalmic solution is an FDA-approved Rho kinase inhibitor indicated for the treatment of ocular hypertension and open-angle glaucoma. In this study, it will be administered once daily in the evening for approximately 14 days.
  • Other: Artificial Tears (AT) — Artificial tears will be used as a placebo control and administered once daily in the evening for approximately 14 days. These drops are not expected to lower intraocular pressure or alter trabecular meshwork structure.
Study Locations (1 sites)
Indiana Universtiy School of Optometry, Bloomington, Indiana 47405 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older * Diagnosis of ocular hypertension or open-angle glaucoma * Eye examination within the past year * For glaucoma subjects: structural (optic nerve and/or retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma * Best-corrected visual acuity of 20/100 or better * Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT) * Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable) Exclusion Criteria: * Known intolerance to netarsudil ophthalmic solution * Corneal scarring or active corneal disease that would interfere with imaging * Inability to tolerate gonioscopy procedures * Females of childbearing potential who are not using effective contraception or are not sterile * Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion
Conditions High Risk Cardiovascular Disease, Hypert...
Phase PHASE3
Enrollment 11000
Locations 1190 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Zilebesiran — Zilebesiran will be administered SC
  • Drug: Placebo — Placebo will be administered SC

Primary Outcomes

  • Time to First Occurrence of a Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Heart Failure (HF) Event (Hospitalization for HF or Urgent HF Visit) (Up to approximately 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-09-22
Completion: 2030-09-23
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 11000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alnylam Pharmaceuticals
Collaborators: Hoffmann-La Roche
Principal Investigators:
  • Medical Director (STUDY_DIRECTOR) - Alnylam Pharmaceuticals
Contact Information
Study Contact:
Clinical Trial Information Line
1-877-ALNYLAM
clinicaltrials@alnylam.com
Clinical Trial Information Line
1-877-256-9526
clinicaltrials@alnylam.com
Interventions
  • Drug: Zilebesiran — Zilebesiran will be administered SC
  • Drug: Placebo — Placebo will be administered SC
Study Locations (1190 sites)
Clinical Trial Site, Birmingham, Alabama 35205 United States
Clinical Trial Site, Birmingham, Alabama 35211 United States
Clinical Trial Site, Fairhope, Alabama 36532 United States
Clinical Trial Site, Foley, Alabama 36535 United States
Clinical Trial Site, Huntsville, Alabama 35801 United States
Clinical Trial Site, Huntsville, Alabama 35805 United States
Clinical Trial Site, Sheffield, Alabama 35660 United States
Clinical Trial Site, Chandler, Arizona 85224 United States
Clinical Trial Site, Gilbert, Arizona 85296 United States
Clinical Trial Site, Glendale, Arizona 85308 United States
Eligibility Criteria
Inclusion Criteria: * Is 18 years or older for patients with established cardiovascular disease (CVD) * Is 55 years or older for patients with high risk for CVD * Has established CVD (defined as coronary, cerebrovascular, or peripheral artery disease) or high risk for CVD * Has treated hypertension on stable therapy with at least 2 standard of care antihypertensive medications, one of which must be a thiazide, thiazide-like, or loop diuretic Exclusion Criteria: * Has known history of secondary hypertension * Has symptomatic orthostatic hypotension * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3×upper limit of normal (ULN) * Has total serum bilirubin \>1.5×ULN * Has international normalized ratio (INR) \>1.5 * Has serum potassium \>4.8 mEq/L * Has estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m\^2
Conditions Postoperative Delirium (POD), Intraopera...
Phase NA
Enrollment 3432
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

In older patients having surgery, postoperative delirium (an acute disturbance in awareness, attention, or cognition) is common and associated with short-term and long-term morbidity and mortality. The pathophysiology of postoperative delirium is multifactorial - but presumably includes inadequate brain perfusion during surgery caused by low intraoperative blood pressure. Therefore, the investigators aim to determine in a multicenter randomized-controlled trial if targeted intraoperative blood pressure management reduces postoperative delirium. The investigators will test the primary hypothesis that maintaining intraoperative mean arterial pressure at 85 mmHg or higher - compared to at 65 mmHg or higher (routine care) - reduces the incidence of postoperative delirium within the first 3 postoperative days in older patients with arterial hypertension having non-cardiac surgery. The investigators will also assess the duration of postoperative delirium, postoperative complications, and the patients' quality of life. The results of this trial will have a direct impact on guidelines and will help improve medical care for patients and the patients' health. Effective strategies to prevent postoperative delirium are missing. The hypothesis that targeted intraoperative blood pressure management can help reduce postoperative delirium is supported by previous observational studies and interventional trials. This trial is supposed to confirm the causal relationship between intraoperative blood pressure and postoperative delirium and to demonstrate the effectiveness of the therapeutic approach.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Other: MAP at 85 mmHg or higher (intervention group) — In patients assigned to the intervention group, clinicians will be instructed to maintain MAP at 85 mmHg or higher. The trial intervention will start at the beginning of induction of general anesthesia and ends at the end of surgery.
  • Other: MAP at 65 mmHg or higher (control group) — In patients assigned to the control group, clinicians will be instructed to maintain MAP at 65 mmHg or higher. The trial intervention will start at the beginning of induction of general anesthesia and ends at the end of surgery.

Primary Outcomes

  • Delirium within the first 3 postoperative days (binary outcome) (within the first 3 postoperative days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-21
Completion: 2030-09
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3432 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf
Collaborators: Germany's Federal Ministry of Research, Technology and Space (BMFTR)
Contact Information
Study Contact:
Karim Kouz, MD
+4940741052415
k.kouz@uke.de
Bernd Saugel, MD
+4940741052415
b.saugel@uke.de
Karim Kouz, MD
+4940741052415
k.kouz@uke.de
• Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg
Interventions
  • Other: MAP at 85 mmHg or higher (intervention group) — In patients assigned to the intervention group, clinicians will be instructed to maintain MAP at 85 mmHg or higher. The trial intervention will start at the beginning of induction of general anesthesia and ends at the end of surgery.
  • Other: MAP at 65 mmHg or higher (control group) — In patients assigned to the control group, clinicians will be instructed to maintain MAP at 65 mmHg or higher. The trial intervention will start at the beginning of induction of general anesthesia and ends at the end of surgery.
Study Locations (1 sites)
• Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Hamburg, Germany
Eligibility Criteria
Inclusion Criteria: To be eligible for trial inclusion, patients must: * 1\) be able to provide informed consent, AND * 2\) be ≥65 years old, AND * 3\) be scheduled for elective non-cardiac surgery with general anesthesia that is expected to last ≥120 minutes, AND * 4\) have chronic arterial hypertension requiring antihypertensive medication OR have a systolic arterial pressure ≥140 mmHg or diastolic arterial pressure ≥90 mmHg on a measurement performed within the previous year, AND * 5\) be at high risk for postoperative delirium because: American Society of Anesthesiologists physical status class III or IV OR Charlson Comorbidity Index ≥3 points (please see Appendix 1) OR frailty (documented in medical records or clinical diagnosis) Exclusion Criteria: Patients that meet one or more of the following exclusion criteria cannot participate in the trial: * solid organ transplant surgery * intracranial surgery * surgery in sitting position * sepsis * surgery in the previous 30 days * previous participation in ASPIRE-85
Conditions Intrahepatic Cholangiocarcinoma (Icc)
Phase PHASE2
Enrollment 38
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to evaluate the efficacy and safety of Apatinib and Adebrelimab in Combination With chemotherapy in patients with advanced intrahepatic cholangiocarcinoma (ICC)

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Apatinib and Adebrelimab in Combination With chemotherapy — Patients would receive Adebrelimab (IV 1200mg q3w) and apatinib (PO 250mg qd) plus GEMOX (up to 6 cycles) in 21day cycles. Apatinib and Adebrelimab would be maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.

Primary Outcomes

  • objective response rate (ORR) (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-04-25
Completion: 2028-10-01
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 38 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Principal Investigators:
  • Changzhen Shang, M.D, PhD (PRINCIPAL_INVESTIGATOR) - Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Changzhen Shang, M.D, PhD
+86-20-3407 0701
shchzh2@mail.sysu.edu.cn
Interventions
  • Drug: Apatinib and Adebrelimab in Combination With chemotherapy — Patients would receive Adebrelimab (IV 1200mg q3w) and apatinib (PO 250mg qd) plus GEMOX (up to 6 cycles) in 21day cycles. Apatinib and Adebrelimab would be maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
Study Locations (1 sites)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong China
Eligibility Criteria
Inclusion Criteria: * 1\. Provided informed consent and sign the informed consent form; * 2\. Male or female, Aged 18-75 years (counted on the date of signing informed consent); * 3\. Histologically or cytologically confirmed ICC; * 4\. The patient is not a candidate for surgery, or the disease has progressed after prior surgery and/or local treatment. * 5\. No previous systematic treatment for advanced ICC. Exceptions include patients who relapsed more than 6 months after adjuvant chemotherapy following radical resection. Local regional therapy (including but not limited to surgery, radiotherapy, hepatic artery embolization, TACE, hepatic arterial infusion, radiofrequency ablation, cryoablation or percutaneous ethanol injection) must have been completed at least 4 weeks prior to baseline radiological scanning, and any toxicity (except alopecia) induced by local regional therapy must have resolved to ≤ Grade 1 in accordance with National Cancer Institute - Common Terminology Criteria for Adverse Event version 5.0 (NCI-CTCAE v5.0); * 6\. Have at least one measurable lesion (in accordance with RECIST v1.1, major diameter ≥ 10 mm of the measurable lesion in spiral CT scan or short diameter of swollen lymph node ≥ 15 mm; the lesion with previous local therapy can be used as target lesion after the progression is confirmed in accordance with RECIST v1.1) * 7\. Child-Pugh class: Grade A; * 8\. ECOG-PS score: 0-1; * 9\. With a life expectancy of ≥ 12 weeks; * 10\. Adequate major organ function without severe hematologic, cardiac, pulmonary, hepatic, renal, or bone marrow dysfunction, and no immunodeficiency disease; * 11\. If subjects have active hepatitis B (HBV) infection: HBV- deoxyribonucleic acid (DNA) must be \< 500 IU/mL (or must be \< 2500 copy/mL if copy/mL is the only unit available in the study site) and are willing to receive antiviral therapy throughout the study (treatment in accordance with local standard of care, e.g., entecavir); * 12\. Women of childbearing potential must agree to abstain from heterosexual intercourse or use reliable contraception from the time of signing informed consent until at least 120 days after the last study drug administration. A negative serum pregnancy test (HCG) must be confirmed within 7 days before starting study treatment. Lactating women are excluded; * 13\. Men with female partners of childbearing potential must agree to abstain from heterosexual intercourse or use reliable contraception from the time of signing informed consent until at least 120 days after the last study drug administration. Men must also agree not to donate sperm during this period. For men whose partners are pregnant, condom use is required without additional contraception; Exclusion Criteria: * 1\. Known hepatocellular carcinoma, Combined Hepatocellular and Intrahepatic Cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, fibrolamellar carcinoma of liver; * 2\. Other active malignant tumor except ICC within 5 years or simultaneously. Cured localized tumor, for example, basal cell carcinoma of skin, squamous cell carcinoma of skin, superficial bladder cancer, carcinoma in situ of prostate, carcinoma in situs of cervix, breast cancer in situ may be enrolled; * 3\. Planning to or previously received organ or allogenic bone marrow transplantation; * 4\. Treatment of other investigational product(s) within 28 days prior to the start of study treatment; * 5\. Previous treatment with Immune Checkpoint Inhibitors: Prior use of any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints), including anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies (including topical use). * 6\. Moderate-to-severe ascites with clinical symptoms, i.e., requiring therapeutic puncture or drainage, or Child-Pugh score \>2, except the subjects with small amount of ascites in radiological examination but free from clinical symptoms; uncontrolled or moderate to severe pleural effusion, pericardial effusion. * 7\. History of gastrointestinal bleeding within 6 months prior to the start of study treatment or clear tendency of gastrointestinal bleeding; * 8\. Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment; * 9\. Known genetic or acquired hemorrhage (e.g., coagulation dysfunction) or thrombotic tendency, for example, subject with hemophilia; current or recent (within 10 days prior to the start of study treatment) use of full-dose of oral or intravenous anticoagulant or thrombolytic drug for the purpose of treatment (preventive use of low-dose aspirin or low molecular weight heparin is allowed); * 10\. Current or recent (within 10 days prior to the start of study treatment) use of aspirin (\> 325 mg/day, maximum dose for antiplatelet) or dipyridamole, ticlopidine, clopidogrel and cilostazol; * 11\. Thrombosis or thromboembolic event within 6 months prior to the start of study treatment, for example, cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), pulmonary embolism; * 12\. Cardiac clinical symptom or disease that is not well controlled; * 13\. Hypertension that cannot be well controlled through antihypertensive drugs, allowing to reach the above parameters by the use of antihypertensive therapy; previous hypertensive crisis or hypertensive encephalopathy; * 14\. Major vascular disease within 6 months prior to the start of study treatment (for example, aortic aneurysm requiring surgical repair or peripheral arterial thrombosis in recent days); Serious, unhealed or splitting wound and active ulcer or untreated bone fracture; Major surgical therapy within 4 weeks prior to the start of study treatment (except diagnosis), or planned major surgery during the study; * 15\. Evidence on intraperitoneal pneumatosis that can not be explained by puncture or recent surgery; * 16\. Previous or current presence of metastasis to central nervous system; Metastatic disease involving main airway or blood vessels (e.g. Vena cava tumor invasion or complete occlusion of the major portal vein due to HCC, the major portal vein is defined as the part of portal vein between the union of the splenic and superior mesenteric veins and the first bifurcation into the left and right vein) or high-volume mediastinal tumor mass located in the center (distance from carina \<30 mm); * 17\. History of hepatic encephalopathy; Current interstitial pneumonia or interstitial lung disease, or history of interstitial pneumonia or interstitial lung disease which required hormonal therapy, or other pulmonary fibrosis that may interfere with the judgement and treatment of immune-related pulmonary toxicity; organizing pneumonia (e.g., obliterative bronchiolitis), pneumoconiosis, drug related pneumonitis, idiopathic pneumonia, subjects with evidence on active pneumonia or serious pulmonary function impairment on thoracic computed tomography (CT) in screening period (previous radiation pneumonitis in the radiation area will be allowed); active tuberculosis; * 18\. Active autoimmune disease or history of autoimmune disease and may relapse (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism \[with the exception that it can be controlled by hormone replacement therapy\]). Subjects with skin disease that do not require systemic treatment are eligible, for example, leukoderma, psoriasis, alopecia; subjects with controlled type 1 diabetes by insulin are eligible; subjects with asthma that has been completely resolved in childhood and don't need any treatment are eligible, but subjects with asthma that require a bronchodilator as medical intervention are not eligible; * 19\. Use of immunosuppressive medication within 14 days prior to the start of study treatment, or systemic corticosteroid therapy to achieve the objective of immunosuppression (Prednisone

SPYRAL GEMINI Pilot Study

NCT06907147
Recruiting
Conditions Hypertension, Vascular Diseases, Cardiov...
Phase NA
Enrollment 175
Locations 18 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Multi-Organ Denervation Gemini System — After angiography according to standard procedures, subjects are treated with renal denervation followed by hepatic denervation.

Primary Outcomes

  • Change in office blood pressure (From baseline to 36 months post-procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-01
Completion: 2029-12-22
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 175 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medtronic Vascular
Contact Information
Study Contact:
Cecile Mahoney
+17635051057
Cecile.C.Mahoney@medtronic.com
Maria Perlas
650-723-2094
mperlas@stanford.edu
Stanford Hospital and Clinics
Isabella Ko
650-497-2367
idko@stanford.edu
Stanford Hospital and Clinics
Interventions
  • Device: Multi-Organ Denervation Gemini System — After angiography according to standard procedures, subjects are treated with renal denervation followed by hepatic denervation.
Study Locations (18 sites)
Stanford Hospital and Clinics, Stanford, California 94305 United States
Orlando Health Heart & Vascular Institute, Orlando, Florida 32806 United States
BayCare Health System Mease Countryside Hospital, Safety Harbor, Florida 34695 United States
Piedmont Heart Institute, Atlanta, Georgia 30309-1281 United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215 United States
Henry Ford Providence Hospital, Southfield, Michigan 48075-4818 United States
North Mississippi Medical Center, Tupelo, Mississippi 38801-4934 United States
Renown Regional Medical Center, Reno, Nevada 89502 United States
Virtua Our Lady of Lourdes Hospital, Camden, New Jersey 08103 United States
University of North Carolina (UNC) Memorial Hospital, Chapel Hill, North Carolina 27599 United States
Eligibility Criteria
Inclusion Criteria: All Subjects (both cohorts): 1. ≥18 and ≤80 years of age. 2. Diagnosed with HTN and has a baseline office SBP ≥150 mmHg and \<180 mmHg and an office DBP ≥ 90 mmHg. 3. 24-hour average SBP ≥140 mmHg and \<170 mmHg measured by ABPM at Baseline. Exclusion Criteria: 1. Individual lacks appropriate renal artery OR common hepatic artery anatomy. 2. Prior renal or hepatic denervation. 3. History of NYHA Class III or IV heart failure within 6 months of screening visit. 4. Stroke or transient ischemic attack (TIA) within 6 months of screening visit or any history of stroke leading to permanent disability. 5. Documented Type 1 diabetes or use of insulin within 6 months. 6. Secondary cause of hypertension. 7. Documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement. 8. Estimated glomerular filtration rate (eGFR) of \<40 9. Pregnant, nursing or planning to become pregnant during the study. 10. Primary pulmonary arterial hypertension. 11. History or evidence of active / suspected chronic liver or biliary disease. 12. Current or chronic pancreatitis.
Conditions Persistent Pulmonary Hypertension of New...
Phase PHASE1, PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to evaluate the effectiveness of nebulized magnesium sulfate combined with sildenafil citrate, compared with sildenafil citrate alone, in treating neonates with severe persistent pulmonary hypertension on mechanical ventilation.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Magnesium sulfate — Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes
  • Drug: Sildenafil Citrate — Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
  • Other: Isotonic saline — Nebulized isotonic saline (4 ml) every 15 minutes

Primary Outcomes

  • Change in Oxygenation index (OI) (From baseline to 2, 6, 12, and 24 hours following study drug administration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2021-06-02
Completion: 2025-06-01
Eligibility
Age: 6 Hours – 72 Hours
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sohag University
Principal Investigators:
  • Elsayed Abdelkreem, MD, PhD (PRINCIPAL_INVESTIGATOR) - Sohag University
Contact Information
Study Contact:
Elsayed Abdelkreem, MD, PhD
00201114232126
d.elsayedmohammed@med.sohag.edu.eg
Mostafa Abo-Sidera, MD, PhD
1002028668
aabosdera@yahoo.com
Neonatal Intensive Care Unit, Sohag University Hospital
Interventions
  • Drug: Magnesium sulfate — Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes
  • Drug: Sildenafil Citrate — Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
  • Other: Isotonic saline — Nebulized isotonic saline (4 ml) every 15 minutes
Study Locations (1 sites)
Neonatal Intensive Care Unit, Sohag University Hospital, Sohag, 82524 Egypt
Eligibility Criteria
Inclusion Criteria: * Gestational age ≥ 36 weeks * Birth weight between 2.5 and 4 kg. * Post-natal age between 6 and 72 hours. * PPHN confirmed by echocardiography * Oxygenation index (OI) \> 30 on two occasions at least 15 minutes apart * Connected to Mechanical Ventilation Exclusion Criteria: * Failure to obtain informed consent * Newborns to mothers who received magnesium sulfate within 48 hours before labor. * Congenital heart diseases, other than patent ductus arteriosus and foramen ovale. * Major congenital anomalies (including congenital diaphragmatic hernia and lung hypoplasia). * Prior need for cardiopulmonary resuscitation. * Mean arterial blood pressure (MABP) \< 35 mmHg despite therapy with volume infusions and vasoactive inotropes. * Impaired kidney function. * Prior administration of pulmonary vasodilators. * Gastrointestinal intolerance or bleeding
Conditions Combined Pre- and Post-capillary Pulmona...
Phase PHASE4
Enrollment 64
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH). The study will measure changes in pulmonary vascular resistance, NT-proBNP, 6-minute walk distance, and quality of life (KCCQ scores) over 24 weeks. Participants will be randomly assigned to one of two groups, take study medication for 24 weeks, and undergo regular clinical, laboratory, and safety assessments.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Combination therapy — Macitentan 10mg, Dapagliflozin 10mg or 5mg po tablet q.d. in 24 weeks
  • Drug: Monotherapy — Macitentan placebo, Dapagliflozin 10mg or 5mg po tablet q.d. in 24 weeks

Primary Outcomes

  • Hierarchical outcome component(Change in PVR, Change in NT-proBNP, Change in 6MWD, Change in KCCQ-CSS) (Baseline, 24 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-11-24
Completion: 2027-09-30
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gachon University Gil Medical Center
Contact Information
Study Contact:
Wook-Jin Chung, MD, PhD
82-32-460-3663
heart@gilhospital.com
Wook-Jin Chung, MD,PhD
82-32-460-3663
heart@gilhospital.com
Gachon University Gil Hospital
Interventions
  • Drug: Combination therapy — Macitentan 10mg, Dapagliflozin 10mg or 5mg po tablet q.d. in 24 weeks
  • Drug: Monotherapy — Macitentan placebo, Dapagliflozin 10mg or 5mg po tablet q.d. in 24 weeks
Study Locations (15 sites)
Pusan National University Hospital, Busan, 49241 South Korea
Chungbuk National University Hospital, Chungju, 28644 South Korea
Keimyung University Dongsan Hospital, Daegu, 42601 South Korea
Chungnam National University Hospital, Daejeon, 35015 South Korea
Chonnam National University Hospital, Gwangju, 61469 South Korea
Incheon Sejong Hospital, Incheon, 21080 South Korea
Gachon University Gil Hospital, Incheon, 405-760 South Korea
Seoul National University Hospital, Seoul, 03080 South Korea
Yonsei University Health System, Severance Hospital, Seoul, 03722 South Korea
Asan Medical Center, Seoul, 05505 South Korea
Eligibility Criteria
Inclusion Criteria: \<Screening Visit (Visit 1)\> 1. A male or female adults aged 19 years or older in South Korea 2. LVEF greater than 40% on echocardiogram performed within 12 weeks prior to screening 3. Presence of heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) accompanied by combined pre- and post-capillary pulmonary hypertension (CpcPH) 4. Meeting all of the following criteria on RHC performed within 48 weeks prior to screening: 1. mPAP \> 20 mmHg 2. PVR \> 2 Wood units (WU) 3. PAWP \> 15 mmHg 5. World Health Organization Functional Class (WHO-FC) II or III at the time of screening 6. If taking any of the following medications at the time of screening, the participant must have been on a stable dose for at least 3 months: 1. Renin-angiotensin system inhibitors 2. Beta-blockers 3. Mineralocorticoid receptor antagonists (aldosterone antagonists) 4. Sodium-glucose cotransporter-2 (SGLT2) inhibitors 5. Ivabradine \<Baseline Visit (Visit 2)\> 1\. World Health Organization Functional Class (WHO-FC) II or III at the time of baseline visit Exclusion Criteria: \<Screening Visit (Visit 1)\> 1. Known hypersensitivity to the active ingredients (Macitentan, Dapagliflozin) or any excipients of the investigational medicinal product 2. Pregnant or breastfeeding women, or those who do not agree to use at least two appropriate contraceptive methods\* (self or partner) during the clinical trial period and for 30 days after the last administration of the investigational medicinal product (for male participants, those who do not agree to refrain from sperm donation) \*: a. Surgical sterilization (e.g., vasectomy) or intrauterine device (IUD; copper IUD or hormone-releasing intrauterine system), b. Non-oral hormonal contraceptive or spermicide in combination with a barrier method, c. Cervical cap or diaphragm used in combination with a male condom. 3. Participants with type 1 diabetes mellitus or secondary diabetes mellitus 4. Participants with metabolic acidosis, such as diabetic ketoacidosis 5. Participants diagnosed with pulmonary hypertension other than WHO Group 2 pulmonary hypertension (i.e., WHO Group 1, 3, 4, or 5) 1. Group 1: Pulmonary arterial hypertension 2. Group 3: Pulmonary hypertension associated with lung diseases and/or hypoxia 3. Group 4: Chronic thrombo-embolic pulmonary hypertension 4. Group 5: Pulmonary hypertension with unclear and/or multifactorial mechanisms 6. Participants who meet the following criteria on RHC performed within 12 weeks prior to screening: a. PAWP ≤ 15 mmHg 7. History of taking any of the following medications within 4 weeks prior to screening: 1. Calcium channel blockers 2. Endothelin receptor antagonists 3. Phosphodiesterase type 5 inhibitors (PDE5i) 4. Riociguat 5. Prostacyclin (PC) analogs or prostacyclin receptor agonists 6. Activin signaling inhibitors 8. History of any of the following medical conditions, surgeries, or procedures: 1. Myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention (PCI) within 3 months prior to screening 2. Uncontrolled tachycardia (\>110 bpm) due to atrial fibrillation or atrial flutter 3. History of heart transplantation or implantation of a ventricular assist device, or planned to undergo such procedures 9. eGFR ≤ 30 mL/min/1.73 m² or AST or ALT ≥ 2.5 × ULN 10. Urinary tract infection, genital infection (including fungal infections), or voiding disorder within 24 weeks prior to screening 11. Hemoglobin \< 9 g/dL at the time of screening 12. Participants with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption 13. Known hypersensitivity to soybean oil or history of soybean oil allergy 14. Known hypersensitivity to soy or peanuts 15. Participation in another clinical trial involving administration/application of an investigational medicinal product or medical device within 3 months prior to screening \<Baseline Visit (Visit 2)\> 1. Participants who, upon re-confirmation of inclusion/exclusion criteria at the baseline visit, have any disqualifying condition 2. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in this clinical trial
Conditions Fibrosing Mediastinitis, Pulmonary Hyper...
Phase NA
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Through a randomized controlled trial (RCT) design, this study aiming to evaluated the efficacy and safety of rituximab lymph node injection combined with pulmonary vascular interventional therapy in treating fibrosing mediastinal pulmonary hypertension (FM-PH).Eligible participants were randomly assigned to either the combined treatment group, receiving both pulmonary vascular intervention and rituximab lymph node injection, or the interventional-only group, which received pulmonary vascular intervention alone. At 3, 6, and 12 months post-treatment, the efficacy was assessed based on symptom improvement, hemodynamic changes, lesion volume reduction, etc. Safety was mainly evaluated by comparing adverse event incidence between the two groups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Rituximab Lymph Node Injection Combined with Pulmonary Vascular Intervention — Based on the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed vessels. During the treatment cycle, one lymph node drug injection is administered: 50mg of rituximab is dissolved in 15ml of 5% glucose solution and injected at multiple sites into the identified enlarged mediastinal lymph nodes under ultrasound-guided bronchoscopy.
  • Procedure: Pulmonary Vascular Interventional Therapy — According to the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed pulmonary vessels.

Primary Outcomes

  • Change from Baseline in the Six Minutes Walk Distance at 12 Months. (From enrollment to the end of treatment at 12 months)
  • The incidence of treatment-related serious adverse events (SAE) (During the one-year follow-up period after treatment completion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-10
Completion: 2027-10-31
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Chao Yang Hospital
Collaborators: Beijing Municipal Health Commission
Contact Information
Study Contact:
Juanni Gong, Doctor of Medicine
15801511482
juannigong2018@126.com
Juanni Gong
15801511482
juannigong2018@126.com
Beijing Chaoyang Hospital, Capital Medical University
Interventions
  • Procedure: Rituximab Lymph Node Injection Combined with Pulmonary Vascular Intervention — Based on the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed vessels. During the treatment cycle, one lymph node drug injection is administered: 50mg of rituximab is dissolved in 15ml of 5% glucose solution and injected at multiple sites into the identified enlarged mediastinal lymph nodes under ultrasound-guided bronchoscopy.
  • Procedure: Pulmonary Vascular Interventional Therapy — According to the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed pulmonary vessels.
Study Locations (1 sites)
Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with fibrosing mediastinitis between November 2024 and November 2026, aged between 18 and 85 years. 2. The patient presented with symptoms of chest tightness, shortness of breath, and reduced exercise tolerance. 3. Chest CT revealed mediastinal lymph node compression of the pulmonary artery, with evidence of pulmonary hypertension consistent with the patient's symptoms. 4. The subject signed the informed consent form prior to participation and is able to comply with the study protocol and one-year follow-up. Exclusion Criteria: 1. Currently in the active phase of infection, including but not limited to tuberculosis, Histoplasma capsulatum, and Aspergillus infections; 2. The underlying primary disease, such as sarcoidosis, Behcet's disease, or uncontrolled IgG4-related disease, is currently not well controlled. 3. Before treatment, a large amount of pleural effusion was still present. 4. Pulmonary function tests (PFT) showed FEV1 \<30% of the predicted value, FEV1/FVC \<30%, and DLCO \<30%. 5. There are contraindications to bronchoscopy or endovascular intervention. 6. Complicated by other end-stage organ dysfunction, such as Child-Pugh class C liver function or stage IV chronic renal failure. 7. Complicated by severe immunosuppression.

Global Cardio Oncology Registry

NCT05598879
Recruiting
Conditions Breast Cancer, Hematologic Malignancy, I...
Phase Not Applicable
Enrollment 5000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: anonymized data collection during programmed surveillance clinical follow up — anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform

Primary Outcomes

  • Cardiotoxicity (18 months of prospective follow up)
  • New cardiovascular events (18 months of prospective follow up)
  • Cardiovascular death. (18 months of prospective follow up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-07-01
Completion: 2029-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Cleveland Clinic
Principal Investigators:
  • Diego Sadler, MD FACC (PRINCIPAL_INVESTIGATOR) - The Cleveland Clinic
Contact Information
Study Contact:
Diego Sadler, MD FACC
5613898833
sadlerd@ccf.org
Rohit Moudgil, MD PhD
216-445-1932
moudgir@ccf.org
Diego Sadler, MD FACC
561-389-8833
sadlerd@ccf.org
Cleveland Clinic Florida
Interventions
  • Other: anonymized data collection during programmed surveillance clinical follow up — anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform
Study Locations (1 sites)
Cleveland Clinic Florida, Weston, Florida 33331 United States
Eligibility Criteria
Inclusion Criteria: * New cardio-oncology consultation for breast cancer patients, or * New cardio-oncology consultation for Hodgkin's or non-Hodgkin's lymphoma patients, or * New cardio-oncology consultation for acute or chronic leukemia patients, or * New cardio-oncology consultation for multiple myeloma or AL amyloidosis, or * New cardio-oncology consultations for immune check-point inhibitors cardiac evaluation. * All patients have to be 18 years old or older Exclusion Criteria: * Cardio-oncology patients who have previously had cardio-oncology evaluation and follow up by the investigators. * Minors less than 18 years old. * Inability or unwillingness to consent to participate